Effect of increased bile flow and bile acid secretion on the hepatic elimination of sodium valproate in the cat.
The effect of increased bile flow and hepatic bile acid flux on the systemic clearance and hepatic elimination of intravenously administered sodium valproate was studied in the bile fistula cat. Taurochenodeoxycholic acid (TCDC), tauro-3 alpha, 7 beta-dihydroxy-12-keto-5 beta-cholanoic acid (T12K), SC-2644, and secretin were infused intravenously to vary bile flow and biliary bile acid secretion. Control animals were infused with 0.15 mol/l NaCl. Less than 1% of the drug administered to controls appeared as unchanged valproate in the bile over 6 h. Although SC-2644, T12K, and secretin significantly increased biliary excretion of valproate, it did not exceed 2% of the intravenous dose. Biliary clearance was directly related to the rate of bile flow, but not to the bile acid flux. By contrast, 18-19% of the dose appeared in bile as metabolite in controls, and none of the choleretic agents significantly increased this percentage. As a result, systemic clearance of valproate was unaltered. We conclude that the movement of unchanged valproate into bile is consistent with a process of simple diffusion. The fact that choleretic agents do not increase metabolite excretion into bile suggests that metabolite formation may be the rate-limiting step in the hepatic elimination of valproate, rather than transport and excretion of metabolites into bile.
D000818:Animals; D001646:Bile / Q000502:physiology*; D001647:Bile Acids and Salts / Q000378:metabolism*; D002415:Cats; D002756:Cholagogues and Choleretics / Q000494:pharmacology; D005260:Female; D008099:Liver / Q000378:metabolism*; D008297:Male; D012633:Secretin / Q000494:pharmacology; D013655:Taurochenodeoxycholic Acid / Q000494:pharmacology; D014635:Valproic Acid / Q000378:metabolism*
D001647:Bile Acids and Salts; D002756:Cholagogues and Choleretics; D012633:Secretin; D013655:Taurochenodeoxycholic Acid; D014635:Valproic Acid